Results 181 to 190 of about 197,779 (358)

Familial SYNGAP1 variants define the boundaries of a complex neurodevelopmental disorder with epilepsy

open access: yesEpilepsia, EarlyView.
Abstract Objective SYNGAP1‐related disorders are common neurodevelopmental conditions characterized by autism spectrum disorder, developmental delay, intellectual disability, and a range of generalized seizure types. Disease‐causing variants in SYNGAP1 typically occur de novo. This study aims to characterize inherited cases of SYNGAP1‐related disorders.
Alicia G. Harrison   +10 more
wiley   +1 more source

Trans-synaptic molecular context of NMDA receptor nanodomains. [PDF]

open access: yesNat Commun
Anderson MC   +6 more
europepmc   +1 more source

Shank, a Novel Family of Postsynaptic Density Proteins that Binds to the NMDA Receptor/PSD-95/GKAP Complex and Cortactin [PDF]

open access: bronze, 1999
Scott Naisbitt   +8 more
openalex   +1 more source

WONOEP XVII appraisal: Targeting network excitability beyond the synapse ‐Neurotransmitter, ionic, and electro ‐diffusions

open access: yesEpilepsia, EarlyView.
Abstract Epilepsy affects approximately 1% of the population worldwide, and although medications are effective in the majority of cases, seizures persist in approximately 30% of patients. Despite the effort to develop new antiseizure drugs, the rate of pharmacoresistance in patients has not diminished over the past 3 decades. There is thus a real unmet
Vincent Magloire   +9 more
wiley   +1 more source

Anti-NMDA Receptor Encephalitis: A Narrative Review. [PDF]

open access: yesBrain Sci
Pădureanu V   +6 more
europepmc   +1 more source

Topiramate for the treatment of neonatal seizures and beyond

open access: yesEpilepsia, EarlyView.
Abstract Acute symptomatic neonatal seizures are one of the most common neurological disorders in newborns admitted to neonatal intensive care units and require prompt treatment. Up to 50% of neonatal seizures are refractory to first‐line medications such as phenobarbital (PB), and another 30% fail second‐line therapy.
Wolfgang Löscher, Janet S. Soul
wiley   +1 more source

Drug discovery and preclinical testing of drug candidates for developmental and epileptic encephalopathies

open access: yesEpilepsia, EarlyView.
Abstract Drug development for developmental and epileptic encephalopathies (DEEs) follows different strategies on one hand including disease‐targeting precision medicine approaches considering the genetic variants and pathomechanisms in DEEs and on the other hand including therapeutic approaches with novel targets or second‐generation drug candidates ...
Heidrun Potschka, Daniel Pérez‐Pérez
wiley   +1 more source

Home - About - Disclaimer - Privacy